Drug intelligence / Profile preview

BI 137882

Development stage: Discontinued
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 137882 is a small molecule drug that was developed by Boehringer Ingelheim for the treatment of respiratory diseases, specifically chronic obstructive pulmonary disease (COPD). The drug underwent Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. However, development of BI 137882 has been discontinued and it is no longer being pursued for any indication. The specific molecular target and mechanism of action have not been publicly disclosed[1][2][3].

Beyond the preview

Go deeper on BI 137882.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 137882.

Explore the full profile